Microlyte DualGuard for Wound Care

(SAGGA Trial)

This trial tests a new wound dressing called Microlyte DualGuard to determine its effectiveness in healing skin graft donor sites. It compares this dressing to a standard foam dressing in preventing infections and reducing pain, itching, and scarring. Individuals with a skin graft donor site on their thigh due to a chronic wound, burn, or surgery may qualify. Researchers will monitor participants for 12 weeks to assess wound healing and any side effects. As an unphased trial, this study provides a unique opportunity to contribute to medical research and potentially benefit from an innovative treatment.

Research has shown that Microlyte® DualGuard, a type of wound dressing, is safe for use. This dressing belongs to the Microlyte family, which the FDA has approved for its germ-fighting and pain-relieving properties. It contains a small amount of silver, aiding in wound healing without causing harm. Previous studies have found that similar products in the Microlyte line are well-tolerated, with no major side effects reported. These findings suggest that Microlyte DualGuard should be safe, given its similarity to other FDA-approved products.¹²³⁴⁵

Microlyte DualGuard is unique because it combines advanced materials to promote faster healing in wound care. Unlike standard foam dressings like Allevyn, which primarily focus on moisture management, Microlyte DualGuard incorporates a highly absorbent matrix infused with antimicrobial agents. This innovative composition not only helps maintain optimal moisture levels but also actively combats infection, potentially leading to quicker recovery times. Researchers are excited about this treatment because it offers a dual-action approach that both protects the wound and accelerates healing, which could significantly improve outcomes for patients needing wound care.

Research has shown that Microlyte DualGuard, which participants in this trial may receive, effectively aids wound healing. In earlier studies, 72% of wounds treated with Microlyte healed significantly better, with wound size shrinking by an average of 66% in three weeks. By 12 weeks, 91% of these wounds were either completely healed or nearly healed. The product aims to lower infection risk and reduce pain, both crucial for quicker recovery. This evidence suggests that Microlyte DualGuard could be a promising option for healing certain types of wounds.⁵⁶⁷⁸⁹